Clinical Trials

120 enrolled

Advanced Solid Malignancies

NCT05938296 2025-11-19

oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection

29 enrolled

Solid Tumor

NCT05033522 2025-10-23

ALIVE

Phase 2/3 Suspended

150 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03392064 2025-10-15

A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC

6 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT05494697 2025-10-14

Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

90 enrolled

Pancreatic Neoplasms

NCT03417921 2025-10-01

Pancreatic

60 enrolled

Pancreatic Neoplasms

NCT04693546 2025-09-26

PREVENT

Suspended

12,000 enrolled

Colorectal Neoplasms

NCT04418167 2025-09-03

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

DermatologicEndocrineHead & NeckThoracic

71 enrolled

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Thyroid Carcinoma, Anaplastic

NCT05055518 2025-06-27

APL-102 Capsule in Patients With Advanced Solid Tumors

30 enrolled

Advanced Solid Tumor

NCT05958199 2025-06-27

A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

131 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT05603572 2025-06-05

KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)

148 enrolled

Fibrolamellar hepatocellular carcinoma, Carcinoma, Hepatocellular

NCT05571969 2025-05-07

Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors

40 enrolled

Advanced Solid Tumors

NCT05191667 2025-02-13

AN0025 and Chemoradiotherapy Combination in Esophageal Cancer

32 enrolled

Esophageal Neoplasms

NCT05416749 2024-11-20

A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors

216 enrolled

Solid Tumors

NCT05123534 2024-09-19

A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG

15 enrolled

CNS

Diffuse Intrinsic Pontine Glioma

NCT04946864 2024-08-19

A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer

65 enrolled

Breast

Breast Neoplasms

NCT04120246 2024-07-10

Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer

24 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT05643690 2024-06-06

Urine Sample Collection for Validation of the AnchorDx UriFind™ Bladder Cancer Assay

Suspended

77 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT04714983 2024-04-09

DNX-2440 for Resectable Colorectal Liver Metastasis

BreastDermatologicGastrointestinalGenitourinarySarcoma

30 enrolled

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Melanoma, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT02546102 2024-04-03

Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma

Phase 3 Suspended

234 enrolled

CNS

Glioblastoma

NCT03932253 2024-03-27

MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)

79 enrolled

Dermatologic

Melanoma

NCT05067257 2024-03-18

Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer

120 enrolled

Cancer Pain, Pain, Pain, Intractable

NCT05361915 2024-03-18

Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer

100 enrolled

Genitourinary

Prostatic Neoplasms

NCT05168904 2024-02-08

A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)

MyeloidOther hematologic neoplasm

210 enrolled

Leukemia, Myelodysplastic Syndromes

NCT05756556 2024-02-01

T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

68 enrolled

Dermatologic

Melanoma

NCT04711161 2024-01-23

First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.

73 enrolled

Gynecologic

Ovarian Neoplasms

NCT04996030 2024-01-23

A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia

Other hematologic neoplasm

16 enrolled

Leukemia, Promyelocytic, Acute

NCT04505813 2024-01-16

Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma

9 enrolled

Plasma cell

Multiple Myeloma

NCT04053062 2024-01-05

LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer

12 enrolled

Genitourinary

Castrate-Resistant Prostate Cancer

NCT05138458 2023-11-13

IMAGINE

LymphoidOther hematologic neoplasm

40 enrolled

DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT03659669 2023-10-23

REVEAL

Suspended

272 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04485052 2023-10-23

Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia

Other hematologic neoplasm

222 enrolled

Leukemia, Myeloid, Acute

NCT03859752 2023-09-22

TR1801-ADC in Patients With Tumors That Express c-Met

15 enrolled

Unspecified Adult Solid Tumor, Protocol Specific

NCT01796795 2023-09-14

Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients

LymphoidOther hematologic neoplasm

102 enrolled

Warts

NCT03229876 2023-07-24

Safety and Efficacy Evaluation of CD19-UCART

Phase NA Suspended

20 enrolled

Lymphoma, Non-Hodgkin, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03002103 2023-04-26

A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer

Phase 3 Suspended

420 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04650451 2023-04-20

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

220 enrolled

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT01933815 2023-02-22

Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma